Table 2.

Association between cf DNA concentration (ng/mL) and patients’ characteristics

	cfDNA concentration (MN kit) (ng/ml)	P value	cfDNA concentration (QIAGEN kit) (ng/ml)	P value
Gender
Male vs. female	13.96 (4.67) vs. 13.88 (3.69)	0.94	19.21 (6.59) vs. 19.01 (5.67)	0.91
Smoking
Yes vs. no	13.96 (4.55) vs. 13.9 (4.05)	0.97	19.17 (6.1) vs. 19.08 (6.1)	0.96
Current status
Alive vs. dead	13.22 (4.56) vs. 16.21 (3.4)	0.05	17.56 (5.78) vs. 23.49 (6.28)	0.007
Recurrence
Yes vs. no	15.81 (3.45) vs. 12.06 (4.7)	0.008	21.93 (6.09) vs. 16.27 (5.7)	0.007
Stage
II and III vs. IV	7.66 (2.5) vs. 14.37 (3.84)	0.005	11.43 (2.05) vs. 19.66 (5.84)	0.02
Metastasis
Non metastatic vs. Metastasis to one organ	7.94 (3.81) vs. 13.69 [3]	0.02	11.1 (3.52) vs. 18.71 (4.73)	0.01
Non metastatic vs. Metastasis to two organs	7.94 (3.81) vs. 16.5 (2.29)	0.001	11.1 (3.52) vs. 23.5 (4.98)	0.002
Non metastatic vs. Metastasis to three organ	7.94 (3.81) vs. 19.18 (3.45)	< 0.001	11.1 (3.52) vs. 25.92 (6.24)	< 0.001
Metastasis to one organ vs. Metastasis to two organs	13.69 [3] vs. 16.5 (2.29)	0.33	18.71 (4.73) vs. 23.5 (4.98)	0.26
Metastasis to one organ vs. Metastasis to three organs	13.69 [3] vs. 19.18 (3.45)	0.004	18.71 (4.73) vs. 25.92 (6.24)	0.01
Metastasis to two organs vs. Metastasis to three organs	16.5 (2.29) vs. 19.18 (3.45)	0.57	23.5 (4.98) vs. 25.92 (6.24)	0.87